Lipoprotein(a) and Benefit of PCSK9 Inhibition in Emergency Complex Higher-risk and Indicated Patients

Abstract

Objective

There is a large population of patients classified as complex higher-risk and indicated patients (CHIPs) in China with a poor prognosis. The treatment of these patients is complex and challenging, especially when acute cardiac events occur, such as acute coronary syndrome (ACS) or heart failure. Pharmacotherapy and some mechanical circulatory support (MCS) therapeutic devices can provide stable hemodynamic support for CHIPs-percutaneous coronary intervention (PCI). LDL-C is an important pathogenic factor in atherosclerosis, and the target of blood lipid control. Recent studies have revealed that lipoprotein(a) [Lp(a)], which is formed when a covalent bond between apolipoprotein(a) and apolipoprotein B-100 is made, produces an LDL-like particle. This particle is an independent risk factor for the development of atherosclerosis, and is closely correlated to stent thrombosis and restenosis. Furthermore, this requires active intervention. PCSK9 inhibitors have been used in lipid-lowering treatment, and preventing atherosclerosis. The present study explores the efficacy of PCSK9 inhibitors in CHIPs-ACS, and the association between the change in Lp(a) and survival after 2 years of follow-up.

Methods

The present real-world, prospective control study enrolled 321 CHIPs-ACS who underwent emergency PCI from August 2019 to November 2020, and these patients were followed up for 2 years. These patients were divided into two groups: PCSK9 group (n=161) given the combined PCSK9 inhibitor (140 mg of evolocumab every 2 weeks) and statins-based therapy, and SOC group (n=160) treated with statin-based lipid-lowering therapy alone. Then, the change in lipid index was measured, and the cardiovascular (CV) event recurrence rate was evaluated after one month and 2 years. Afterwards, the contribution of serum lipid parameters, especially the Lp(a) alteration, in patients with earlier initiation of the PCSK9 inhibitor to the CV outcome was analyzed.

Results

The LDL-C level was significantly reduced in both groups: 52.3% in the PCSK9 group and 32.3% (P<0.001) in the SOC group. It is noteworthy that the Lp(a) level decreased by 13.2% in the PCSK9 group, but increased by 30.3% in the SOC group (P<0.001). Furthermore, the number of CV events was not significantly different between the PCSK9 and SOC groups after the 2-year follow-up period. In the PCSK9 group, the Lp(a) reduction was associated with the baseline Lp(a) levels of the patients (r² =−0.315, P<0.001). Moreover, the decrease in Lp(a) contributed to the decline in CV events in patients who received ACS CHIPs-PCI, and the decrease in Lp(a) level was independent of the LDL-C level reduction.

Conclusion

The early initiation of PCSK9 inhibitors can significantly reduce the LDL-C and Lp(a) levels in ACS CHIPs-PCI. However, further studies are needed to confirm whether PCSK9 inhibitors can reduce the incidence of CV disease in CHIPs.

Keywords

PCSK9 inhibitor / complex higher-risk and indicated patients / lipoprotein(a) level / low-density lipoprotein cholesterol level / 2-year cardiovascular event rate

References

[1] ValkF, BekkeringS, KroonJ, et al.. Oxidized Phospholipids on Lipoprotein(a) Elicit Arterial Wall Inflammation and an Inflammatory Monocyte Response in Humans. Circulation, 2016, 134(8): 611-624

[2] NordestgaardBG, JohnCM, KausikR, et al.. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J, 2010, 31(23): 2844-2853

[3] PedenJF, HopewellJ, ClarkeR. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med, 2009, 361(26): 2518-2528

[4] Kamstrup, PiaR, Tybærg-Hansen, et al.. Genetically Elevated Lipoprotein(a) and Increased Risk of Myocardial Infarction. JAMA, 2009, 301: 2331-2339

[5] PattiG, PasceriV, ColonnaG, et al.. Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial. J Am Coll Cardiol, 2007, 49(12): 1272-1278

[6] Zheng B, Jiang J, Liu H, et al. Efficacy and safety of serial atorvastatin load in Chinese patients undergoing elective percutaneous coronary intervention: results of the ISCAP. Eur Heart J Suppl, 2015(suppl_B):B47–B56

[7] JangY, ZhuJ, GeJ, et al.. Preloading with atorvastatin before percutaneous coronary intervention in statin-naïve Asian patients with non-ST elevation acute coronary syndromes: A randomized study. J Cardiol, 2014, 63(5): 335-343

[8] BerwangerO, SantucciEV, de BarrosE, SilvaPGM, et al.. Effect of Loading Dose of Atorvastatin Prior to Planned Percutaneous Coronary Intervention on Major Adverse Cardiovascular Events in Acute Coronary Syndrome: The SECURE-PCI Randomized Clinical Trial. JAMA, 2018, 319(13): 1331-1340

[9] Zheng W, Zhang YJ, Bu XT, et al. LDL-cholesterol goal attainment under persistent lipid-lowering therapy in northeast China: Subgroup analysis of the dyslipidemia international study of China (DYSIS-China). Medicine (Baltimore), 201,96(46):e8555

[10] François M, Colin B, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Eur Heart J, 2019(1):1

[11] Chinese expert consensus on lipid management of very high-risk atherosclerotic cardiovascular disease patients. Chin J Cardiol (Chinese), 2020,48(4):280–286

[12] China cholesterol education program (CCEP) expert advice for the management of dyslipidaemias to reduce cardiovascular risk (2019). Chin J Intern Med (Chinese), 2019,59(1):18–22

[13] YongjunW, ChunxueW, ZhongrongM. Chinese guidelines for secondary prevention of ischemic stroke and transient ischemic attack 2014. Chin J Neurol (Chinese), 2015, 48(04): 258-273

[14] BlomDJ, HalaT, BologneseM. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med, 2014, 370: 1809-1819

[15] KckA, SwA, GpB, et al.. Evolocumab for Early Reduction of LDLCholesterol Levels in Patients With Acute Coronary Syndromes (EVOPACS). J Am Coll Cardiol, 2019, 74(20): 2452-2462

[16] LeuckerTM, BlahaMJ, JonesSR, et al.. Effect of Evolocumab on Atherogenic Lipoproteins During the Peri- and Early Postinfarction Period: A Placebo-Controlled, Randomized Trial. Circulation, 2020, 142: 419-421

[17] MjkA, MssB, RpgsB, et al.. Long-Term Efficacy and Safety of Evolocumab in Patients With Hypercholesterolemia. J Am Coll Cardiol, 2019, 74(17): 2132-2146

[18] LiuYQ, LiDD, ChaiM, et al.. Real world effectiveness of PCSK-9 inhibitors combined with statins versus statins-based therapy among patients with very high risk of atherosclerotic cardiovascular disease in China (RWE-PCSK study). J Gerratr Cardiol, 2021, 18(4): 261-270

[19] O’DonoghueML, FazioS, GiuglianoRP, et al.. Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk Insights From the FOURIER Trial. Circulation, 2019, 139: 1483-1492

[20] Duarte LauF, GiuglianoRP. Lipoprotein(a) and its Significance in Cardiovascular Disease: A Review. JAMA Cardiol, 2022, 7(7): 760-769

[21] EnkhmaaB, AnuuradE, ZhangW, et al.. The roles of apo(a) size, phenotype, and dominance pattern in PCSK9-inhibition-induced reduction in Lp(a) with alirocumab. J Lipid Res, 2017, 58(10): 2008-2016

[22] TsimikasS, PhilipL, GordtsSM, et al.. Statin therapy increases lipoprotein(a) levels. Eur Heart J, 2020, 41(24): 2275-2284

[23] WattsGF, ChanDC, DentR, et al.. Factorial effects of evolocumab and atorvastatin on lipoprotein metabolism. Circulation, 2017, 135(4): 338-351

[24] WattsGF, ChanDC, SomaratneR, et al.. Controlled study of the effect of proprotein convertase subtilisin-kexin type 9 inhibition with evolocumab on lipoprotein(a) particle kinetics. Eur Heart J, 2018, 39(27): 2577-2585

[25] SharmaM, RedpathGM, WilliamsMJA, et al.. Recycling of Apolipoprotein(a) after PlgRKT-Mediated endocytosis of lipoprotein(a). Circ Res, 2017, 120(7): 1091-1102